Allergan Hits Lupin With 2nd Eye Drop Patent Suit

Law360, New York (May 20, 2011, 3:54 PM EDT) -- Allergan Inc. and two Japanese pharmaceutical companies sued Lupin Ltd. in Delaware on Wednesday to stop the company's proposed generic version of pinkeye treatment Zymar, following a similar suit to halt the manufacture of a stronger dosage.

Allergan, together with Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd., claim that Lupin's bid for U.S. Food and Drug Administration approval to market a version of gatifloxacin ophthalmic solution infringes two patents.

U.S. Patent Numbers 6,333,045 and 5,880,283 cover the treatment, which Allergan sells in a 0.3...
To view the full article, register now.